
Dr Alexis Willett, Policy Manager at Breakthrough Breast Cancer, says: "This research shows that the vast majority of breast cancer specialists surveyed were confident that patients in their breast units and who could benefit from Aromatase Inhibitors (AIs) were receiving them in line with NICE guidance.
Click here for full Story http://www.medicalnewstoday.com/articles/124316.php |